Fighting kids’ cancer, one voucher at a time

There are few new cancer drugs to treat kids, and not much research is being done.


CNBC Highlights Lack Of Cancer Treatments Approved For Children.

Meg Tirrell reported in depth on Friday for the CNBC (11/24) website on the difficulty childhood cancer patients can face in obtaining pharmaceutical treatments, as few new medicines are aimed at fighting childhood cancers and most cancer medicines are not targeted for use in children. Many doctors thus have to resort to off-label use of existing drugs. CNBC explored the “compassionate use” system and the subsequent Creating Hope Act which expedited FDA reviews for pediatric medicines and awards vouchers for pharmaceutical companies whose products are approved. Examining industry efforts, CNBC said that in 2012 Roche’s Genentech unit set up a pediatric oncology drug development team, which is headed by Raphael Rousseau. In an interview, Rousseau told CNBC, “Historically, people have been reluctant (to expose) children to drugs, trying to protect them from research when really the right thing is to protect them through research.” CNBC also talked to Amgen’s Dr. Lisa Bollinger, who joined the company in 2012, after years with the FDA, to “really look at their entire pipeline and look at opportunities to study their products in the pediatric population.” Tirrell also highlighted the issue in a CNBC (11/24) broadcast.

See on Scoop.itAdvocacy Action & Issues in Cancer


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: